TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16034820
Drug: Nutrition (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition (intravenous glucose with amino acids)
Study: 16034820
Drug: Glucose only
Normalized name: Glucose only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose only (intravenous glucose without amino acids)
Study: 12167548
Drug: Standard inpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inpatient withdrawal treatment using clonidine plus symptomatic medication
Study: 2209499
Drug: 1.5 l
Normalized name: NUTREN 1.5 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 l Golytely preparation
Study: 2209499
Drug: 3 l
Normalized name: D3 Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 l Golytely preparation
Study: 2209499
Drug: 1.5 l
Normalized name: NUTREN 1.5 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 l Golytely preparation (post-study routine)
Study: 7232842
Drug: Radiotherapy, chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy, chemotherapy, and MER
Study: 31661974
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (N-acetylcysteine and mitochondrial agents)
Study: 31109838
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both
Study: 9676035
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (no G-CSF treatment)
Study: 23788069
Drug: Uncertainty about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncertainty about receiving medicine when pushing the PCA button
Study: 21255195
Drug: Mianserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (20 mg; p.o.)
Study: 12713062
Drug: SQV-SGC 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV-SGC 1200 mg three times daily plus two NRTIs
Study: 12713062
Drug: SQV-SGC 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV-SGC 1600 mg twice daily plus two NRTIs
Study: 12713062
Drug: SQV-SGC 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV-SGC 1200 mg twice daily plus NFV 1250 mg twice daily plus one NRTI
Study: 10738041
Drug: Large-volume leukapheresis
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-volume leukapheresis (LVL) with heparin
Study: 8805090
Drug: d,l‐fenfluramine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l‐fenfluramine hydrochloride (60 mg orally)
Study: 1637895
Drug: Prophylaxis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis therapy for pneumocystis carinii pneumonia
Study: 1637895
Drug: High-dose 3-azido-3-deoxythymidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 3-azido-3-deoxythymidine (AZT)
Study: 1637895
Drug: Low-dose 3-azido-3-deoxythymidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 3-azido-3-deoxythymidine (AZT)
Study: 6706305
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at 2.1 mg X kg‐1 X day‐1
Study: 6706305
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at 4.2 mg X kg‐1 X day‐1
Study: 6706305
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at 8.4 mg X kg‐1 X day‐1
Study: 6706305
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at 16.2 mg X kg‐1 X day‐1
Study: 6706305
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) at 16.9 mg X kg‐1 X day‐1
Study: 30266030
Drug: iCBT (internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT (internet-delivered cognitive behavioral therapy)
Study: 22709747
Drug: Standard optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard optimal medical therapy
Study: 20006197
Drug: ED-administered antibiotics
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED-administered antibiotics
Study: 17559725
Drug: Infliximab therapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab therapy for 6 weeks
Study: 15770833
Drug: Cefepime 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 150 mg/kg/day
Study: 15770833
Drug: Ceftazidime 150
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime 150 mg/kg/day + Amikacin 15 mg/kg/day
Study: 12390444
Drug: Cetirizine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (0.25 mg/kg)
Study: 7405925
Drug: Post-antibiotic therapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-antibiotic therapy
Study: 31840969
Drug: Ocular cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular cleansing with sterile gauze (group A) 3 times daily for 48 hours
Study: 31840969
Drug: Ocular cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular cleansing with Iridium® baby gauze containing Echinacea angustifolia (group B) 3 times daily for 48 hours
Study: 23024190
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg infusion)
Study: 15221295
Drug: Gated SPECT
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gated SPECT with 99mTc‐sestamibi injection
Study: 12235452
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of enoxaparin (1.5 mg/kg once daily for 4 days)
Study: 12235452
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of enoxaparin (1.5 mg/kg)
Study: 9602765
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose radiotherapy of 5 Gy at the operation field preoperatively
Study: 7747098
Drug: Enhanced potency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced potency inactivated poliovirus vaccine (EIPV)
Study: 20961474
Drug: Wellness Workshop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellness Workshop (WW) CD‐ROM + Treatment as Usual (TAU)
Study: 14745389
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution sprayed on the major duodenal papilla (placebo)
Study: 9014067
Drug: Heparin-dihydroergotamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-dihydroergotamine 0.5 mg + 5,000 IU twice a day
Study: 1396108
Drug: Buprenorphine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.4 mg or 0.8 mg/70 kg)
Study: 1396108
Drug: Buprenorphine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.4 mg or 0.8 mg/70 kg) + Naloxone (0.4 mg or 0.8 mg/70 kg)
Study: 3888241
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 or 2.5 mg)
Study: 28214653
Drug: NACT followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NACT followed by CCRT (cisplatin 80 mg/m2 d1 and fluorouracil 800 mg/m2 civ d1‐5 for two cycles before CCRT)
Study: 28214653
Drug: CCRT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT alone (cisplatin 80 mg/m2 every 3 weeks concurrently with radiotherapy)
Study: 25277597
Drug: Cyclosporine treatment
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine treatment for 2 years
Study: 21684425
Drug: Pandemic live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic live attenuated influenza vaccine (PLAIV) against the influenza A (H1N1) virus
Study: 21684425
Drug: H5N2 pandemic
Normalized name: pangamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N2 pandemic live attenuated influenza vaccine (PLAIV)
Study: 21684425
Drug: Seasonal live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal live attenuated influenza vaccine (LAIV)
Study: 18307373
Drug: Duloxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (10 mg IV infusion over 30 minutes or 60 mg orally) with fluvoxamine (100 mg orally once daily)
Study: 18307373
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg orally twice daily)
Study: 18307373
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg orally once daily)
Study: 18307373
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg orally)
Study: 17000242
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin therapy
Study: 17000242
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin therapy (enoxaparin sodium)
Study: 10509768
Drug: Breakfast cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast cereal (80 g for men, 60 g for women) consumed at breakfast for six weeks
Study: 8948303
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) and parenteral gold therapy (PGT)
Study: 8948303
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and parenteral gold therapy (PGT)
Study: 28452665
Drug: Home-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-delivered cognitive-behavioral therapy (CBT) for depression
Study: 21791142
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (1.7 g daily for 3 months)
Study: 15886433
Drug: Medical record
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical record (MR) - data collected hourly
Study: 9800145
Drug: Oral methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylnaltrexone 19.2 mg/kg
Study: 9800145
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 0.05 mg/kg
Study: 6193350
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MDL‐899
Study: 6193350
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MDL‐899 with 100 mg atenolol
Study: 23688137
Drug: Sensorimotor enrichment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensorimotor enrichment group (daily olfactory/tactile stimulation and paired sensory exercises)
Study: 16946455
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruption (STI) of antiretroviral therapy
Study: 12723462
Drug: Trazodone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone with low-dose ritonavir (200 mg each, four doses)
Study: 12723462
Drug: Trazodone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone with low-dose ritonavir
Study: 30371800
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + goserelin
Study: 26690356
Drug: Letrozole (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (0.1 mg/kg)
Study: 26690356
Drug: Cabergoline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (100 µg/kg)
Study: 17351370
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg twice daily for 4 weeks
Study: 17351370
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg twice daily for 4 weeks
Study: 16318148
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion plus Chinese medicine
Study: 16318148
Drug: Simple Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Chinese medicine
Study: 9773700
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oxycodone and 10 mL 0.5% bupivacaine (group OB)
Study: 9773700
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 0.5% bupivacaine (group B)
Study: 2496213
Drug: Low-dose calcium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcium and phosphorus (5 mM each; 20 mg/dl of Ca and 15.5 mg/dl of P)
Study: 2496213
Drug: High-dose calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose calcium and phosphorus (15 mM each; 60 mg/dl of Ca and 46.5 mg/dl of P)
Study: 2496213
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (low and high-dose)
Study: 21666556
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone administered in 100 mL of physiologic saline given intravenously 20 minutes before anesthesia induction
Study: 21666556
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL NaCl 0.9% in 100 mL of physiologic saline (control group)
Study: 19417877
Drug: Ketoprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (50 mg)
Study: 14968598
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with background infusion (3 ml PCEA, lock out 30 min, continuous infusion 5 ml/hr)
Study: 14968598
Drug: Infuser group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infuser group (continuous infusion 5 ml/hr)
Study: 14968598
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with background infusion
Study: 9160657
Drug: Interferon alpha2b
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha2b 3 million U three times weekly for 12 months
Study: 7695058
Drug: terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 120 mg once a day
Study: 3302705
Drug: Cop 1
Normalized name: COP 1
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cop 1 (20 mg daily for two years)
Study: 3302705
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline alone daily for two years)
Study: 3302705
Drug: Cop 1
Normalized name: COP 1
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cop 1 (20 mg daily for two years) among less disabled patients (Kurtzke score 0 to 2)
Study: 3302705
Drug: Cop 1
Normalized name: COP 1
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cop 1 (20 mg daily for two years) among more disabled patients (Kurtzke score 3 to 6)
Study: 3302705
Drug: Cop 1
Normalized name: COP 1
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cop 1 (20 mg daily for two years) among less disabled patients
Study: 3302705
Drug: Cop 1
Normalized name: COP 1
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cop 1 (20 mg daily for two years) among more disabled patients
Study: 22802308
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg per day) for 3 months
Study: 22802308
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg per day) for 3 months
Study: 19874198
Drug: Odanacatib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (all doses)
Study: 18310545
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone and rituximab
Study: 18310545
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone alone
Study: 12209697
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha2b (HDI)
Study: 12209697
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon alpha2b (LDI)
Study: 12209697
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha2b (HDI) and Low-dose interferon alpha2b (LDI)
Study: 10522576
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block (15 mL bupivacaine 0.5%) and 1 mL normal saline i.v. (FNB group)
Study: 10522576
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg (1 mL) ketorolac i.v. (KT group)
Study: 10522576
Drug: Placebo femoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo femoral nerve block (15 mL normal saline) and 1 mL normal saline i.v. (PL group)
Study: 1970552
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of an i.v. immunoglobulin preparation (ivIg)/kg body weight every other week
Study: 30969452
Drug: Taking joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking joint pain medication
Study: 27329923
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with House Dust Mite allergen extract
Study: 21992121
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 150 mg twice a day
Study: 10767815
Drug: Early vigorous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early vigorous medical exercise therapy (8-week active rehabilitation program with vigorous lumbar stabilizing exercises)
Study: 9370387
Drug: Clonidine 0.2
Normalized name: CLONIDINE 0.2MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.2 mg twice daily
Study: 9370387
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD 300 mg daily
Study: 3943266
Drug: Lanoxin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanoxin (0.5 mg)
Study: 3943266
Drug: Lanoxicaps (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanoxicaps (0.4 mg)
Study: 30923022
Drug: 2-week supply
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week supply of nicotine patches and/or lozenges (NRT)
Study: 29277895
Drug: Enzalutamide (ENZ)
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide (ENZ) and CCX771 (CXCR7 inhibitor) combination treatment
Study: 29277895
Drug: CCX771 (CXCR7
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX771 (CXCR7 inhibitor)
Study: 22447495
Drug: CT-D (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-D (Cognitive Therapy targeting overestimations of danger)
Study: 22447495
Drug: CT-R (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-R (Cognitive Therapy targeting inflated beliefs of personal responsibility)
Study: 11787924
Drug: Transdermal 17‐beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17‐beta oestradiol 50 microg/day for 21 days (cyclical therapy)
Study: 11787924
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal 17‐beta oestradiol 50 microg/day
Study: 9480174
Drug: Insulin dependent
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dependent diabetes mellitus (IDDM)
Study: 9480174
Drug: Non insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non insulin dependent diabetes mellitus (NIDDM)
Study: 31431080
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous microwave ablation
Study: 29506157
Drug: Isoglycemic intravenous
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoglycemic intravenous glucose infusion (IIGI)
Study: 27533305
Drug: IIGI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIGI with glucagon infusion (0.8 ng/kg/min from 0 to 25 minutes)
Study: 24857100
Drug: Weekly carboplatin/paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly carboplatin/paclitaxel X 5 and 41.4 Gy concurrent radiotherapy followed by surgery
Study: 20975104
Drug: High-molecular-weight (HMW)
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-molecular-weight (HMW) carbohydrate solution
Study: 20975104
Drug: Low-molecular-weight (LMW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight (LMW) carbohydrate solution
Study: 20975104
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between HMW and LMW solutions
Study: 17953788
Drug: Citrulline (CIT)
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citrulline (CIT) (all doses)
Study: 16514811
Drug: Allicor (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allicor (a long‐acting garlic drug) for 12 months
Study: 7577484
Drug: Clodronate 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1500 mg
Study: 14690159
Drug: Clodronate 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 900 mg
Study: 9059473
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled salbutamol for four weeks